81 related articles for article (PubMed ID: 13679030)
1. STI-571: an anticancer protein-tyrosine kinase inhibitor.
Roskoski R
Biochem Biophys Res Commun; 2003 Oct; 309(4):709-17. PubMed ID: 13679030
[TBL] [Abstract][Full Text] [Related]
2. Label-free detection of small-molecule-protein interactions by using nanowire nanosensors.
Wang WU; Chen C; Lin KH; Fang Y; Lieber CM
Proc Natl Acad Sci U S A; 2005 Mar; 102(9):3208-12. PubMed ID: 15716362
[TBL] [Abstract][Full Text] [Related]
3. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins.
Carroll M; Ohno-Jones S; Tamura S; Buchdunger E; Zimmermann J; Lydon NB; Gilliland DG; Druker BJ
Blood; 1997 Dec; 90(12):4947-52. PubMed ID: 9389713
[TBL] [Abstract][Full Text] [Related]
4. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.
Druker BJ; Tamura S; Buchdunger E; Ohno S; Segal GM; Fanning S; Zimmermann J; Lydon NB
Nat Med; 1996 May; 2(5):561-6. PubMed ID: 8616716
[TBL] [Abstract][Full Text] [Related]
5. The minute chromosome (Phl) in chronic granulocytic leukemia.
NOWELL PC
Blut; 1962 Apr; 8():65-6. PubMed ID: 14480647
[No Abstract] [Full Text] [Related]
6. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein.
Pendergast AM; Quilliam LA; Cripe LD; Bassing CH; Dai Z; Li N; Batzer A; Rabun KM; Der CJ; Schlessinger J
Cell; 1993 Oct; 75(1):175-85. PubMed ID: 8402896
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia.
Ren R
Nat Rev Cancer; 2005 Mar; 5(3):172-83. PubMed ID: 15719031
[TBL] [Abstract][Full Text] [Related]
8. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.
Rowley JD
Nature; 1973 Jun; 243(5405):290-3. PubMed ID: 4126434
[No Abstract] [Full Text] [Related]
9. Chronic myeloid leukemia: reminiscences and dreams.
Mughal TI; Radich JP; Deininger MW; Apperley JF; Hughes TP; Harrison CJ; Gambacorti-Passerini C; Saglio G; Cortes J; Daley GQ
Haematologica; 2016 May; 101(5):541-58. PubMed ID: 27132280
[TBL] [Abstract][Full Text] [Related]
10. The role of interferon-alpha in the treatment of chronic myeloid leukemia.
Kujawski LA; Talpaz M
Cytokine Growth Factor Rev; 2007; 18(5-6):459-71. PubMed ID: 17703986
[TBL] [Abstract][Full Text] [Related]
11. The development of imatinib as a therapeutic agent for chronic myeloid leukemia.
Deininger M; Buchdunger E; Druker BJ
Blood; 2005 Apr; 105(7):2640-53. PubMed ID: 15618470
[TBL] [Abstract][Full Text] [Related]
12. Glycaemic abnormalities induced by small molecule tryosine kinase inhibitors: a review.
Mugiya T; Mothibe M; Khathi A; Ngubane P; Sibiya N
Front Pharmacol; 2024; 15():1355171. PubMed ID: 38362147
[TBL] [Abstract][Full Text] [Related]
13. Personalized tumor combination therapy optimization using the single-cell transcriptome.
Tang C; Fu S; Jin X; Li W; Xing F; Duan B; Cheng X; Chen X; Wang S; Zhu C; Li G; Chuai G; He Y; Wang P; Liu Q
Genome Med; 2023 Dec; 15(1):105. PubMed ID: 38041202
[TBL] [Abstract][Full Text] [Related]
14. Privileged fragment-based design, synthesis and in vitro antitumor activity of imatinib analogues.
Jiang H; Wang Y; Jiang M; Yao L
Turk J Chem; 2023; 47(2):426-435. PubMed ID: 37528931
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and molecular docking of cysteine-based sulphonamide derivatives as antimicrobial agents.
Egbujor MC; Okoro UC; Okafor SN; Egu SA; Amasiatu IS; Egwuatu PI; Umeh OR; Ibo EM
Res Pharm Sci; 2022 Feb; 17(1):99-110. PubMed ID: 34909048
[TBL] [Abstract][Full Text] [Related]
16. Review of the Synthesis and Anticancer Properties of Pyrazolo[4,3-
Bernat Z; Szymanowska A; Kciuk M; Kotwica-Mojzych K; Mojzych M
Molecules; 2020 Aug; 25(17):. PubMed ID: 32872493
[TBL] [Abstract][Full Text] [Related]
17. Role of membrane-embedded drug efflux ABC transporters in the cancer chemotherapy.
Gupta SK; Singh P; Ali V; Verma M
Oncol Rev; 2020 Jul; 14(2):448. PubMed ID: 32676170
[TBL] [Abstract][Full Text] [Related]
18. Biological Activity Evaluation of Some New Benzenesulphonamide Derivatives.
Eze FU; Okoro UC; Ugwu DI; Okafor SN
Front Chem; 2019; 7():634. PubMed ID: 31620427
[TBL] [Abstract][Full Text] [Related]
19. New carboxamide derivatives bearing benzenesulphonamide as a selective COX-II inhibitor: Design, synthesis and structure-activity relationship.
Ugwu DI; Okoro UC; Ahmad H
PLoS One; 2017; 12(9):e0183807. PubMed ID: 28922386
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
